RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sinopharm Group Co - Stock

Sinopharm Group Co ROE 2024

Sinopharm Group Co ROE

0.12

Ticker

1099.HK

ISIN

CNE100000FN7

WKN

A0N99U

In 2024, Sinopharm Group Co's return on equity (ROE) was 0.12, a -3.08% increase from the 0.13 ROE in the previous year.

Sinopharm Group Co Aktienanalyse

What does Sinopharm Group Co do?

Sinopharm Group Co Ltd is one of the largest Chinese companies in the healthcare industry and was founded in 1998. With its headquarters in Beijing, it has been a significant player in the global healthcare sector for many years and operates in various business areas. The company's history dates back to the 1940s when the original company, China National Pharmaceutical Industry Corporation, was founded. It was later transformed into China National Pharmaceutical Group and eventually renamed Sinopharm Group. Sinopharm's business model is designed to promote healthcare in China while expanding internationally. The company's key business areas include pharmaceutical research and development, drug manufacturing, and the import and export of pharmaceutical products. Overall, Sinopharm Group operates in various sectors, including the production of biological drugs, diagnostic products, medical devices, and medical consumables. Additionally, the company is involved in providing healthcare services such as hospital management and health tourism. An important part of Sinopharm's business is the export of drugs and other medical products. The company has established a global presence and maintains businesses and collaborations with companies in Asia, Europe, North America, and Africa. Furthermore, Sinopharm Group has established several subsidiaries to focus on specialized markets and products better. On the product side, Sinopharm offers a wide range of medications, health products, and medical devices. Some of the most well-known products include anti-cancer drugs, diabetes medications, vaccines, and blood products. The company also invests in research and development of new drugs and is involved in numerous clinical trials. The success of Sinopharm is also based on its close collaboration with the Chinese government. The company works closely with local and national authorities to meet the demand for healthcare products and services in China. The Chinese government also supports the company and promotes its expansion into other countries. Overall, Sinopharm Group has become a significant player in the global healthcare industry in recent years. The company has a strong presence in China and a growing international presence. With a wide range of products and services and a strong focus on research and development, Sinopharm Group is well-positioned to continue growing and adapting to the demands of the healthcare sector. Sinopharm Group Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Sinopharm Group Co's Return on Equity (ROE)

Sinopharm Group Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Sinopharm Group Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Sinopharm Group Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Sinopharm Group Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Sinopharm Group Co Stock

What is the ROE (Return on Equity) of Sinopharm Group Co this year?

The ROE of Sinopharm Group Co this year is 0.12 undefined.

How has the Return on Equity (ROE) of Sinopharm Group Co developed compared to the previous year?

The ROE of Sinopharm Group Co has increased by -3.08% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Sinopharm Group Co?

A high ROE indicates that Sinopharm Group Co generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Sinopharm Group Co?

A low ROE can indicate that Sinopharm Group Co is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Sinopharm Group Co affect the company?

A change in ROE (Return on Equity) of Sinopharm Group Co can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Sinopharm Group Co?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Sinopharm Group Co?

Some factors that can influence Sinopharm Group Co's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Sinopharm Group Co pay?

Over the past 12 months, Sinopharm Group Co paid a dividend of 0.9 CNY . This corresponds to a dividend yield of about 4.7 %. For the coming 12 months, Sinopharm Group Co is expected to pay a dividend of 0.98 CNY.

What is the dividend yield of Sinopharm Group Co?

The current dividend yield of Sinopharm Group Co is 4.7 %.

When does Sinopharm Group Co pay dividends?

Sinopharm Group Co pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Sinopharm Group Co?

Sinopharm Group Co paid dividends every year for the past 19 years.

What is the dividend of Sinopharm Group Co?

For the upcoming 12 months, dividends amounting to 0.98 CNY are expected. This corresponds to a dividend yield of 5.1 %.

In which sector is Sinopharm Group Co located?

Sinopharm Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinopharm Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinopharm Group Co from 8/13/2024 amounting to 0.87 CNY, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Sinopharm Group Co pay the last dividend?

The last dividend was paid out on 8/13/2024.

What was the dividend of Sinopharm Group Co in the year 2023?

In the year 2023, Sinopharm Group Co distributed 0.872 CNY as dividends.

In which currency does Sinopharm Group Co pay out the dividend?

The dividends of Sinopharm Group Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinopharm Group Co

Our stock analysis for Sinopharm Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinopharm Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.